Integration of steroid and growth factor pathways in breast cancer: Focus on signal transducers and activators of transcription and their potential role in resistance

Molecular Endocrinology

Volumn 21, Issue 7, 2007, Pages 1499-1512

  Silva, Corinne M ^a,b   Shupnik, Margaret A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; DNA; ESTROGEN; GROWTH FACTOR; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN; STEROID;

BREAST CANCER; DNA BINDING; ESTROGEN ACTIVITY; GENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR MODULATORS; FEMALE; GROWTH SUBSTANCES; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MODELS, BIOLOGICAL; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS; STEROIDS; TRANSCRIPTION, GENETIC;

EID: 34347229109     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0109     Document Type: Short Survey

References (141)

1. Hennighausen L, Robinson GW 2005 Information networks in the mammary gland. Nat Rev Mol Cell Biol 6:715-725
2. Shillingford JM, Hennighausen L 2001 Experimental mouse genetics: answering fundamental questions about mammary gland biology. Trends Endocrinol Metab 12:402-408
3. Hennighausen L, Robinson GW 1998 Think globally, act locally: the making of a mouse mammary gland. Genes Dev 12:449-455
4. Visvader J, Lindeman G 2003 Transcriptional regulators in mammary gland development and cancer. Int J Biochem Cell Biol 35:1034-1051
5. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA 2001 Mechanisms of estrogen action. Physiol Rev 81:1535-1565
6. Couse JF, Korach KS 1999 Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev [Erratum (1999) 20:459] 20:358-417
7. Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS 1999 A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-α. Cancer Res 59:1869-1876
8. Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O 1998 Generation and reproductive phenotypes of mice lacking estrogen receptor β. Proc Natl Acad Sci USA 95:15677-15682
9. Herynk M, Fuqua S 2004 Estrogen receptor mutations in human disease. Endocr Rev 25:869-898
10. Katzenellenbogen BS, Katzenellenbogen JA 2000 Estrogen receptor α and β: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2:335-344
11. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F 2001 Estrogen receptor β inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120-4130
12. Murphy LC, Watson PH 2006 Is oestrogen receptor-β a predictor of endocrine therapy responsiveness in human breast cancer? Endocr Relat Cancer 13:327-334
13. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM 2005 Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97:1254-1261
14. Carroll JS, Brown M 2006 Estrogen receptor target gene: an evolving concept. Mol Endocrinol 20:1707-1714
15. Acconcia F, Kumar R 2006 Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238:1-14
16. Bjornstrom L, Sjoberg M 2005 Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19:833-842
17. Harrington WR, Kim SH, Funk CC, Madak-Erdogan Z, Schiff R, Katzenellenbogen JA, Katzenellenbogen BS 2006 Estrogen dendrimer conjugates that preferentially activate extranuclear, nongenomic versus genomic pathways of estrogen action. Mol Endocrinol 20:491-502
18. Lange CA 2004 Making sense of cross-talk between steroid hormone receptors and intracellular signaling pathways: who will have the last word? Mol Endocrinol 18:269-278
19. Shupnik MA 2004 Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23:7979-7989
20. Pedram A, Razandi M, Levin E 2006 Nature of functional ER at the plasma membrane. Mol Endocrinol 20:1996-2009
21. Vivacqua A, Bonofiglio D, Recchia AG, Musti AM, Picard D, Ando S, Maggiolini M 2006 The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17β-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631-646
22. Filardo EJ, Graeber CT, Quinn JA, Resnick MB, Giri D, DeLellis RA, Steinhoff MM, Sabo E 2006 Distribution of GPR30, a seven membrane spanning ER, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Cancer Res 12:6359-6366
23. Song RX, Santen RJ 2006 Membrane initiated estrogen signaling in breast cancer. Biol Reprod 75:9-16
24. Kumar R, Wang RA 2002 Protein kinases in mammary gland development and cancer. Microsc Res Tech 59:49-57
25. Troyer KL, Lee DC 2001 Regulation of mouse mammary gland development and tumorigenesis by the ERBB signaling network. J Mammary Gland Biol Neoplas 6:7-21
26. Zaczek A, Brandt B, Bielawski KP 2005 The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20:1005-1015
27. Jackson-Fisher AJ, Bellinger G, Ramabhadran R, Morris JK, Lee KF, Stern DF 2004 ErbB2 is required for ductal morphogenesis of the mammary gland. Proc Natl Acad Sci USA 101:17138-17143
28. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ 2000 Tyrosine kinase signaling in breast cancer: EGF receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203-210
29. Sainsbury J, Malcolm A, Appleton D, Farndon J, Harris A 1985 Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. J Clin Pathol 38:1225-1228
30. Toi M, Osaki A, Yamada H, Toge T 1991 Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur J Cancer 27:977-980
31. Harris J, Lippman M, Veronesi U, Willett W 1992 Breast Cancer. N Engl J Med 327:473-480
32. Neve RM, Lane HA, Hynes NE 2001 The role of overexpressed HER2 in transformation. Ann Oncol 12:S9-S13
33. Sainsbury J, Farndon J, Needham G, Malcolm A, Harris A 1987 Epidermal growth factor receptor status as a predictor of early recurrence and death from breast cancer. Lancet 329:1398-1402
34. Maa M, Leu T, McCarley DJ, Schatzman RC, Parsons S 1995 Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications of the etiology of multiple human cancers. Proc Natl Acad Sci USA 92:6981-6985
35. Tice DA, Biscardi JS, Nickles AL, Parsons SJ 1999 Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96:1415-1420
36. Ottenhoff-Kalff A, Rijksen G, van Beurden E, Hennipman A, Michels A, Staal G 1992 Characterization of protein tyrosine kinases from human breast cancer: involvement of the c-src oncogene product. Cancer Res 52:4773-4778
37. Hayakawa F, Naoe T 2006 SFK-STAT pathway: an alternative and important way to malignancies. Ann NY Acad Sci 1086:213-222
38. Biscardi JS, Belsches AP, Parsons S 1998 Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 21:261-272
39. Biscardi JS, Maa MC, Tice D, Cox ME, Leu TH, Parsons SJ 1999 c-Src mediated phosphorylation of the EGF receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 274:8335-8343
40. Ishizawar RC, Miyake T, Parsons SJ 2006 c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function. Oncogene doi:10.1038/sj.onc. 1210138
41. Defilippi P, Di Stefano P, Cabodi S 2006 p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 16:257-263
42. Nair S, Vadlamudi RK 2007 Emerging significance of ER-coregulator PELP1/MNAR in cancer. Histol Histopathol 22:91-96
43. Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F 2005 Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action. Cancer Res 65:10585-10593
44. Boonyaratanakornkit V, Scott MP, Ribon V, Sherman L, Anderson SM, Maller JL, Miller WT, Edwards DP 2001 Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell 8:269-280
45. Ballare C, Uhrig M, Bechtold T, Sancho E, Di Domenico M, Migliaccio A, Auricchio F, Beato M 1994 Two domains of the progesterone receptor interact with the estrogen receptor and are required for progesterone activation of the c-Src/Erk pathway in mammalian cells. Mol Cell Biol 23:1994-2008
46. Haas D, White SN, Lutz LB, Rasar M, Hammes ST 2005 The modulator of nongenomic actions of the estrogen receptor (MNAR) regulates transcription-independent androgen receptor-mediated signaling: evidence that MNAR participates in G protein-regulated meiosis in Xenopus laevis oocytes. Mol Endocrinol 19:2035-2046
47. Barletta F, Wong CW, McNally C, Lomm BS, Katzenellenbogen BS, Cheskis BJ 2004 Characterization of the interactions of estrogen receptor and MNAR in the activation of cSrc. Mol Endocrinol 18:1096-1108
48. Zhang Z, Kumar R, Santen RJ, Song RX 2004 The role of adapter protein Shc in estrogen non-genomic action. Steroids 69:523-529
49. Riggins RB, Thomas KS, Ta HQ, Wen J, Davis RJ, Schuh NR, Donelan SS, Owen KA, Gibson MA, Shupnik MA, Silva CM, Parsons SJ, Clarke R, Bouton AH 2006 Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b. Cancer Res 66:7007-7015
50. Edwards DP, Boonyaratanakornkit V 2003 Rapid extranuclear signaling by the estrogen receptor (ER): MNAR couples ER and Src to the MAP kinase signaling pathway. Mol Interven 3:12-15
51. Chan SK, Hill ME, Gullick WJ 2006 The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplas 11:3-11
52. Levin ER 2003 Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17:309-317
53. Osborne CK, Shou J, Massarweh S, Schiff R 2005 Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 11:865s-870s
54. Ihle J, Witthuhn B, Quelle F, Yamamoto K, Silvennoinen O 1995 Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 13:369-398
55. Schindler C, Darnell Jr JE 1995 Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64:621-651
56. Silva CM 2004 Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 23:8017-8023
57. Brierley M, Fish EN 2005 STATs: multifaceted regulators of transcription. J Interferon Cytokine Res 25:733-744
58. Darnell Jr JE 1997 STATs and gene regulation. Science 277:1630-1635
59. Decker T, Kovarik P 2000 Serine phosphorylation of STATs. Oncogene 19:2628-2637
60. Weaver AM, Silva CM 2006 Modulation of signal transducer and activator of transcription 5b activity in breast cancer cells by mutation of tyrosines within the transactivation domain. Mol Endocrinol 20:2392-2405
61. Leonard WJ, O'Shea JJ 1998 JAKS AND STATS: biological implications. Annu Rev Immunol 16:293-322
62. Levy DE, Darnell Jr JE 2002 STATs: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651-662
63. Haura EB, Turkson J, Jove R 2005 Mechanisms of disease: insights into the emerging role of STATs in cancer. Nat Clin Pract 2:315-324
64. Desrivieres S, Kunz C, Barash I, Vafaizadeh V, Borghouts C, Groner B 2006 The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition. J Mammary Gland Biol Neoplas 11:75-87
65. Groner B, Hennighausen L 2000 Linear and cooperative signaling: roles for Stat proteins in the regulation of cell survival and apoptosis in the mammary epithelium. Breast Cancer Res 2:149-153
66. Bromberg J 2000 Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res 2:86-90
67. Liu X, Robinson G, Wagner K 1997 Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 11:179-186
68. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park W, Ram PA, Waxman DJ, Davey HW 1997 Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci USA 94:7239-7244
69. Akira S 1999 Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17:138-146
70. Chapman RS, Lourenco PC, Tonner E, Flint DJ, Selbert S, Takeda K, Akira S, Clarke AR, Watson CJ 1999 Suppression of epithelial apoptosis and delayed mammary gland involution in mice with a conditional knockout of Stat3. Genes Dev 13:2604-2616
71. Clarkson R, Boland M, Kritikou E, Lee J, Freeman T, Tiffen P, Watson CJ 2006 The genes induced by STAT3 and STAT5 in mammary epithelial cells define the roles of these STATs in mammary development. Mol Endocrinol 30:675-685
72. Ren S, Cai HR, Li M, Furth P 2002 Loss of STAT5a delays mammary cancer progression in a mouse model. Oncogene 21:4335-4339
73. Humphreys RC, Hennighausen L 2000 Transforming growth factor α and mouse models of human breast cancer. Oncogene 19:1085-1091
74. Iavnilovitch E, Cardiff R, Groner B, Barash I 2004 Deregulation of STAT5 expression and activation causes mammary tumors in transgenic mice. Int J Cancer 112:607-619
75. Kloth MT, Laughlin KK, Biscardi JS, Boerner JL, Parsons SJ, Silva CM 2003 STAT5b, a mediator of synergism between c-Src and the epidermal growth factor receptor. J Biol Chem 278:1671-1679
76. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R 2001 Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513
77. Biscardi JS, Tice DA, Parsons SJ 1999 c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res 76:61-119
78. Bromberg JF, Darnell Jr JE 1998 Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 18:2553-2558
79. Dauer D, Ferraro B, Song L, Yu B, Mora LB, Buettner R, Enkemann S, Jove R, Haura EB 2005 STAT3 regulates genes common to both wound healing and cancer. Oncogene 24:3397-3408
80. Ling X, Arlinghaus RB 2005 Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 65:2532-2536
81. Leslie K, Lang C, Devgan G, Azare J, Berishaj M, Gerald W, Kim Y, Paz K, Darnell JE, Albanese C, Sakamaki T, Pestell RG, Bromberg J 2006 CyclinD1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3. Cancer Res 66:2544-3168
82. Hsieh FC, Cheng G, Lin J 2005 Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 335:292-299
83. Lange CA, Richer JK, Shen T, Horwitz KB 1998 Covergence of progesterone and epidermal growth factor signaling in breast cancer. J Biol Chem 273:31308-31316
84. Stoecklin E, Wissler M, Gouilleux F, Groner B 1996 Functional interactions between Stat5 and the glucocorticoid receptor. Nature 383:726-728
85. Bjornstrom L, Kilic E, Norman M, Parker MG, Sjoberg M 2001 Cross-talk between Stat5b and estrogen receptor-α and -β in mammary epithelial cells. J Mol Endocrinol 27:93-106
86. Carsol JL, Gingras S, Simard J 2002 Synergistic action of prolactin (PRL) and androgen on PRL-inducible protein gene expression in human breast cancer cells: a unique model for functional cooperation between signal transducer and activator of transcription-5 and androgen receptor. Mol Endocrinol 16:1696-1710
87. Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz KB 1998 Covergence of progesterone with growth factor and cytokine signaling in breast cancer. J Biol Chem 273:31317-31326
88. Boerner JL, Gibson M, Fox EM, Posner ED, Parsons SJ, Silva CM, Shupnik M 2005 Estrogen negatively regulates epidermal growth factor (EGF)-mediated signal transducer and activator of transcription 5 signaling in human EGF family receptor-overexpressing breast cancer cells. Mol Endocrinol 19:2660-2670
89. Yamashita H, Iwase H, Toyama T, Fujii Y 2003 Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cells. Oncogene 22:1638-1652
90. Bjornstrom L, Sjoberg M 2002 Signal transducers and activators of transcription as downstream targets of nongenomic estrogen receptor actions. Mol Endocrinol 16:2202-2214
91. Yamashita H, Nishio M, Fujii Y, Iwase H 2004 Dominant-negative STAT5b inhibits growth and induces apoptosis in T47D-derived tumors in nude mice. Cancer Sci 95:662-665
92. Wang Q, Li X, Wang L, Feng Y, Zeng R, Gordoeski G 2004 Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology 145:5568-5579
93. Sato K, Nagao T, Kakumoto M, Kimoto M, Otsuki T, Iwasaki T, Tokmakov AA, Owada K, Fukami Y 2002 Adaptor protein Shc is an isoform-specific direct adaptor of the tyrosine kinase c-Src. J Biol Chem 277:29568-29576
94. Rajhans R, Vadlamudi RK 2006 Comprehensive analysis of recent biochemical and biologic findings regarding a newly discovered protein-PELP1/MNAR. Clin Exp Metastasis 23:1-7
95. Manavathi B, Nair SS, Wang RA, Kumar R, Vadlamudi RK 2005 Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res 65:5571-5577
96. Yeh YT, Ou-Yang F, Chen IF, Yang SF, Wang YY, Chuang HY, Su JH, Hou MF, Yuan SS 2006 STAT3 ser727 phosphorylation and its association with negative estrogen receptor status in breast infiltrating ductal carcinoma. Int J Cancer 118:2943-2947
97. Shen Y, Schlessinger K, Zhu X, Meffre E, Quimby F, Levy D, Darnell Jr JE 2004 Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol Cell Biol 24:407-419
98. Grimley PM, Dong F, Rui H 1999 Stat5a and Stat5b: fraternal twins of signal transduction and transcriptional activation. Cytokine Growth Factor Rev 10:131-157
99. Yamashita H, Xu J, Erwin RA, Farrar WL, Kirken RA, Rui H 1998 Differential control of the phosphorylation state of proline-juxtaposed serine residues Ser725 of Stat5a and Ser730 of Stat5b in prolactin-sensitive cells. J Biol Chem 273:30218-30244
100. Joung YH, Park JH, Park T, Lee CS, Kim OH, Ye SK, Yang UM, Lee KJ, Yang YM 2003 Hypoxia activates signaling transducers and activators of transcription 5 (STAT5) and increases its binding activity to the GAS element in mammary epithelial cells. Exp Mol Med 35:350-357
101. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y, Skaar TC, Gomez B, O'Brien K, Wang Y, Hilakivi-Clarke LA 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling. Oncogene 22:7316-7339
102. Osborne C 1998 Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
103. Shang Y, Brown M 2002 Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468
104. Clarke R, Leonessa F, Welch JN, Skaar TC 2001 Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 53:25-71
105. Howell A, Pippen J, Elledge RM, Mauriac, Vergote I, Jones S, Come SE, Osborne CK, Robertson JF 2005 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer 104:236-239
106. Schiff R, Massarweh SA, Shou J, Bharwani L, Arpino G, Rimawi M, Osborne CK 2005 Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemother Pharmacol 56(Suppl 1):10-20
107. Nicholson KM, Streuli C, Anderson NG 2003 Autocrine signalling through erbB receptors promotes constitutive activation of protein kinase B/Akt in breast cancer cell lines. Breast Cancer Res 81:117-128
108. Knowlden JM, Hurtchenson IA, Jones HE, Madden T, Gee JMW, Harper ME, Barrow D, Wakeling AE, Nicholson RI 2003 Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032-1044
109. Planas-Silva MD, Bruggeman RD, Grenko RT, Stanley Smith J 2006 Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun 341:73-81
110. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM 2005 AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207:139-146
111. Nabha SM, Glaros S, Hong M, Lykkesfeldt AE, Schiff R, Osborne K, Reddy KB 2005 Upregulation of PKC-δ contributes to antiestrogen resistance in mammary tumor cells. Oncogene 24:3166-3176
112. Cabodi S, Moro L, Baj G, Smeriglio M, Di Stefano P, Gippone S, Surico N, Silengo L, Turco E, Tarone G, Defilippi P 2004 p130Cas interacts with estrogen receptor α and modulates non-genomic estrogen signaling in breast cancer cells. J Cell Sci 117:1603-1611
113. Hutcheson IR, Harper ME, Knowlden JM, Barrow D, McClelland RA, Jones HE, Wakeling AE, Gee JM 2001 Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocr Relat Cancer 8:175-182
114. O'Regan RM, Osipo C, Ariazi E, Lee ES, Meeke K, Morris C, Bertucci A, Sarker MA, Grigg R, Jordan VC 2006 Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice. Clin Cancer Res 12:2255-2263
115. Tan M, Lan K, Yao J, Lu C, Sun M, Neal CL, Lu J, Yu D 2006 Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. Cancer Res 66:3764-3772
116. Kushner PJ, Hort E, Shine J, Baxter JD, Greene GL 1990 Construction of cell lines that express high levels of the human estrogen receptor and are killed by estrogens. Mol Endocrinol 4:1465-1473
117. Sharma D, Saxena NK, Davidson NE, Vertino PM 2006 Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res 66:6370-6378
118. Riggins RB, Quilliam LA, Bouton AH 2003 Synergistic promotion of c-Src activation and cell migration by Cas and and-34/BCAR3. J Biol Chem 278:28264-28273
119. Brinkman A, Van der Flier S, Lok EM, Dorssers LC 2002 BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells. J Natl Cancer Inst 92:112-120
120. Van der Flier S, van der Kwast TH, Claassen CJ, Timmermans M, Brinkman A, C H-LS, Foekens JA, Dorssers LC 2001 Immunohistochemical study of the BCAR1/p130Cas protein in non-malignant and malignant human breast tissue. Int J Biol Markers 16:172-178
121. Horvath CM, Darnell JE 1997 The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr Opin Cell Biol 9:233-239
122. Barash I 2006 Stat5 in the mammary gland: controlling normal development and cancer. J Cell Physiol 209:305-313
123. Klinge CM 2000 Estrogen receptor interaction with co-activators and co-repressors. Steroids 65:227-251
124. Hall SH, Hamil KG, French FS 2002 Host defense proteins of the male reproductive tract. J Androl 23:585-597
125. Stoecklin E, Wissler M, Schaetzle D, Pfitzner E, Groner B 1999 Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol 69:195-204
126. Faulds MH, Pettersson K, Gustafsson JA, Haldosen LA 2001 Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol 15:1929-1940
127. Wang Y, Cheng C 2004 ERα and STAT5a cross-talk: interaction through C-terminal portions of the proteins decreases STAT5a phosphorylation, nuclear translocation, and DNA-binding. FEBS Lett 572:238-244
128. Yamamoto T, Matsuda T, Junicho A, Kishi H, Saatcioglu F, Muraguchi A 2000 Crosstalk between STAT3 and estrogen receptor signaling. FEBS Lett 486:143-148
129. Katzenellenbogen BS, Katzenellenbogen J 2002 Defining the "S" in SERMs. Science 295:2380-2381
130. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor regulated transcription. Cell 103:843-852
131. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, Schiff R 2003 Role of the ER coactivator AIB1 and HER2 in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95:353-361
132. Fergal J, Fleming A, Hill K, McDermott E, O'Higgins N, Young L 2004 Differential recruitment of coregulator proteins steroid receptor coactivator and silencing mediator for retinoid and thyroid receptors to the ER and ERE. J Clin Endocrinol Metab 89:375-383
133. Migliaccio A, Piccolo D, Castoria G, Di Domenico M, Bilancio A, Lombardi M, Gong W, Beato M, Auricchio F 1998 Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J 17:2008-2018
134. Narod SA, Foulkes WD 2004 BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676
135. Rosen EM, Fan S, Pestell RG, Goldberg ID 2003 BRCA1 gene in breast cancer. J Cell Physiol 196:19-41
136. Razandi M, Pedram A, Rosen EM, Levin ER 2004 BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. Mol Cell Biol 12:5900-5913
137. Xu J, Fan S, Rosen EM 2005 Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1. Endocrinology 146:2031-2047
138. Vidarsson H, Mikaelsdottir E, Rafner R, Bertwistle D, Ashworth A, Eyfjord E, Valgeirsdottir S 2002 BRCA1 and BRCA2 bind Stat5a and suppress its transcriptional activity. FEBS Lett 532:247-252
139. Ma Y, Katiyar P, Jones LP, Fan S, Zhang Y, Furth P, Rosen EM 2006 The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. Mol Endocrinol 20:14-34
140. Poole AJ, Li Y, Kim YB, Lin SC, Lee WH, Lee EY 2006 Prevention of BRCA mediated mammary tumorigenesis in mice by a progesterone antagonist. Science 314:1467-1470
141. Kim YM, Woo EM, Chong YTE, Homenko DR, Kraus WL 2006 Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor. Mol Endocrinol 20:1479-1493